PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy of Prostate Cancer

[1]  Ying Ding,et al.  Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective , 2022, Frontiers in Oncology.

[2]  M. Rodríguez-Fraile,et al.  The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma. , 2022, Revista espanola de medicina nuclear e imagen molecular.

[3]  C. Vanhove,et al.  Recent advancements in 18F-labeled PSMA targeting PET radiopharmaceuticals. , 2021, Nuclear medicine and biology.

[4]  F. Degoul,et al.  Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials , 2021, Cancers.

[5]  H. Moriwaki,et al.  New pharmaceuticals approved by FDA in 2020: Small-molecule drugs derived from amino acids and related compounds. , 2021, Chirality.

[6]  T. Watabe,et al.  High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients , 2021, Annals of Nuclear Medicine.

[7]  F. Wuest,et al.  Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications , 2020, Pharmaceutics.

[8]  Adriano Duatti,et al.  Review on 99mTc radiopharmaceuticals with emphasis on new advancements. , 2020, Nuclear medicine and biology.

[9]  M. Kruszewski,et al.  Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives , 2020, Molecules.

[10]  C. Buchpiguel,et al.  Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings , 2020, Cancer Imaging.

[11]  S. Vallabhajosula,et al.  Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. , 2020, The oncologist.

[12]  H. Beltran,et al.  Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer , 2019, Cancer.

[13]  H. Wester,et al.  PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy. , 2019, Seminars in nuclear medicine.

[14]  W. Weber,et al.  Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy , 2019, The Journal of Nuclear Medicine.

[15]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[16]  H. Kauczor,et al.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  M. Schwaiger,et al.  Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[18]  Danny F. Martinez,et al.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake , 2016, The Journal of Nuclear Medicine.

[19]  S. Vallabhajosula,et al.  Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. , 2016, Current radiopharmaceuticals.

[20]  Serge K. Lyashchenko,et al.  89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[23]  A. Kozikowski,et al.  A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. , 2009, Journal of medicinal chemistry.

[24]  S. Larson,et al.  Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy , 2008, Journal of Nuclear Medicine.

[25]  M. Manyak,et al.  Indium-111 capromab pendetide in the management of recurrent prostate cancer , 2008, Expert review of anticancer therapy.

[26]  Charles H Seibert.  Translated By , 2006 .